Tranexamic Acid (Cyklokapron): A Canadian Pharmacy Guide

Basic Cyklokapron Information

• INN (International Nonproprietary Name): Tranexamic acid
• Brand Names Available In Canada (English): Cyklokapron; PrCyklokapron; tranexamic acid (generic)
• ATC Code: B02AA02
• Forms & Dosages: Tablets 500 mg standard; injection 100 mg/mL (ampoules 1 g/10 mL commonly used in Canada); occasional 250 mg tablets and oral solution noted in other markets
• Manufacturers In Canada (English): Pfizer (brand Cyklokapron) and generic suppliers from global manufacturers
• Registration Status In Canada (English): Health Canada approved (PrCyklokapron / Cyklokapron)
• OTC / Rx Classification: Prescription only (Rx) in Canada

Latest Research Highlights — Canadian & International

Patients often ask whether new trials change how tranexamic acid is used.

Recent systematic reviews and randomized controlled trials from 2022–2025 continue to support TXA's ability to reduce perioperative and obstetric blood loss and to shorten transfusion needs.

Large trauma meta-analyses, building on earlier CRASH work, show benefit when IV TXA is given early in bleeding trauma, particularly within three hours of injury.

Canadian trauma centres contributed registry data that fed pooled analyses and subgroup updates between 2022 and 2024, helping refine timing recommendations for IV TXA in prehospital and emergency settings.

Canadian gynaecology RCTs (2022–2024) found oral TXA 1,000–1,300 mg three times daily reduced menstrual blood loss by roughly 30–60% compared with placebo in study populations.

Ongoing pharmacovigilance and Health Canada adverse drug reaction reports note rare seizures and thromboembolic events, concentrated among high‑risk patients and with high IV dosing.

Canadian trials and reports emphasise inclusion of diverse populations, with attention to Indigenous and rural cohorts and the implications for equitable access to care.

If precise absolute risk reductions or NNTs are required for clinical decisions, refer to the original trial publications or systematic reviews, as the pooled summaries here do not provide every numeric detail.

Clinical Effectiveness In Canada

Patients want to know whether Cyklokapron works the same here as abroad.

Health Canada has approved Cyklokapron and PrCyklokapron for IV and oral use, and Canadian practice follows international evidence for surgical prophylaxis, obstetric haemorrhage protocols, and oral therapy for heavy menstrual bleeding.

Clinical monographs and the product monograph describe dosing ranges and contraindications; pharmacists and prescribers should check the DIN on packaging and provincial formularies for listing details.

Health Canada Approval — What It Covers: Approval for oral and IV tranexamic acid under the Cyklokapron/PrCyklokapron dossier.

DIN — Where To Find: Listed on product packaging and in provincial drug databases; check the bottle label or pharmacy system for specific DIN.

Provincial Formulary Status: Coverage varies by province; check ODB (Ontario), PharmaCare (BC), RAMQ (Quebec) for outpatient listing and restrictions.

Community pharmacists at chains like Shoppers Drug Mart, Rexall, London Drugs, and Jean Coutu commonly handle prescriptions and provide counselling with bilingual leaflets as standard.

Indications & Expanded Uses — Approved Vs Off‑Label In Canada

People ask whether TXA is only for surgery or if it helps other bleeding problems.

In Canada, approved indications focus on reduction of bleeding in surgical, obstetric, and mucosal bleeding settings, and oral TXA is an established option for heavy menstrual bleeding.

Off‑label uses are encountered in practice, often with specialist input and local protocols.

• Approved — Surgical bleeding prophylaxis; obstetric haemorrhage management; mucosal bleeding control; heavy menstrual bleeding (oral)
• Off‑Label — Hereditary angioedema adjunct therapy; topical or oral use for epistaxis; dental prophylaxis in haemophilia; other specialist-directed uses

When off‑label use is considered, obtain specialist consent, provide bilingual counselling, and document the indication — particularly in rural or remote settings where telemedicine support may be used.

Composition & Brand Landscape

Patients often ask what is in the tablet or ampoule and whether generics are the same.

The active ingredient is tranexamic acid, with oral tablets typically 500 mg and injectable solution 100 mg/mL (commonly supplied as 1 g/10 mL ampoules in Canada).

• Available Forms: 500 mg tablets; 1 g/10 mL IV ampoules (100 mg/mL).
• Packaging Examples: 100‑tablet bottle for oral tablets; 1 g/10 mL ampoule for IV use.

Generic availability tends to reduce copayments, and provincial drug plans reference the DIN and product monograph when deciding reimbursement.

Community pharmacies usually stock tablets for outpatient dispensing, while IV forms are most often held by hospitals and acute care pharmacies.

Contraindications & Special Precautions

People commonly worry about blood clots and seizures when taking TXA.

Absolute contraindications in the product monograph and Health Canada include hypersensitivity to tranexamic acid, active intravascular thrombosis, history of convulsions or seizures, and for injections a history of acquired defective colour vision.

• Absolute Contraindications: Known hypersensitivity; active thrombosis (DVT/PE); history of convulsions; acquired defective colour vision (injection).
• Relative Contraindications: Renal impairment, prior thromboembolic disease, concurrent combined hormonal contraceptives, recent DIC without specialist oversight.
• Renal Adjustment Trigger: Creatinine clearance <30 mL/min — reduce dose or extend interval.

Renal clearance is clinically important because TXA is primarily renally eliminated and dose reductions are required when CrCl is low.

Pharmacists should flag histories of clotting or seizures at dispensing and consult prescribers where risk is elevated, particularly in elderly patients with reduced renal function or those on estrogen-containing therapies.

Dosage Guidelines — Canadian Standard Regimens

Patients ask how to take TXA, and whether timing matters for surgery or periods.

For heavy menstrual bleeding, the common oral regimen in Canada is 1,000–1,300 mg PO up to three times daily for up to five days of the cycle.

For perioperative and trauma settings, IV dosing commonly starts with 1 g IV given early; repeat dosing and infusion rates follow local hospital protocols.

• Timing: Start prior to dental or surgical events when recommended by the prescriber; for HMB start at onset of heavy flow.
• Maximum Durations: HMB: up to 5 days per cycle; short-term surgical/trauma use per protocol.
• Missed Dose: Take as soon as remembered unless close to next dose; do not double up.

Hospital protocols in Ontario and British Columbia specify IV infusion rates and seizure precautions for high-risk patients, and community pharmacists should supply bilingual dosing cards to support adherence.

Interactions Overview

Patients often ask whether they can take TXA with birth control or blood thinners.

The main interaction concerns are with prothrombotic agents such as combined hormonal contraceptives, HRT, and tamoxifen, and with systemic clotting factor concentrates used in haemophilia care.

• Major Interactions: Combined oral contraceptives and other estrogen-containing therapies — increased thrombotic risk; use clinical judgement.
• Moderate Interactions: Concomitant haemostatic concentrates (consult hematology); anticoagulants are not absolute contraindications but warrant monitoring.
• Minor: No notable food interactions; alcohol can worsen mucosal irritation and bleeding.

Pharmacists should reconcile all medications at dispensing, check provincial eHealth records, and consult telepharmacy services for rural patients when interaction uncertainty exists.

Cultural Perceptions & Patient Habits In Canada

Many patients prefer a non‑hormonal option for heavy periods and ask whether TXA will work better than contraception or an IUD.

Online patient communities in Canada frequently discuss TXA positively as an effective alternative to long‑term hormonal therapy or surgery.

Bilingual information in French and English is expected in Quebec and by francophone patients elsewhere, and pharmacies such as Jean Coutu routinely supply French leaflets.

• Common Concerns: Safety (clot risk), fertility questions, cost and coverage, and duration of use.
• Urban Vs Rural: Urban centres have faster specialist access; rural and Indigenous communities may rely on telehealth and hospital supply chains.

Community pharmacists frequently help patients navigate special-authority requests and coverage questions about ODB, PharmaCare, and RAMQ.

Availability & Pricing Patterns

Patients ask where to buy Cyklokapron and how much it costs.

In Canada, Cyklokapron 500 mg tablets and 1 g/10 mL IV ampoules are marketed, with generics also available from multiple suppliers.

Retail prices vary by pharmacy and region and are generally higher than U.S. cash prices per tablet; inpatient IV use is typically hospital-covered while outpatient oral coverage depends on provincial formularies and special-authority rules.

In our online pharmacy, cyklokapron is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Online Canadian pharmacies require a valid prescription for Rx products when applicable and verify DINs during dispensing.

Comparable Medicines And Preferences

When patients ask about alternatives, aminocaproic acid (EACA) is often compared to TXA.

In Canada, TXA is generally favoured for potency, the depth of evidence in trauma and gynaecology, and cost-effectiveness compared with EACA and limited-use agents like aprotinin.

• Pros For TXA: Strong evidence base, used across surgery, trauma and HMB; widely available.
• Cons For TXA: Rare seizure and thrombotic risks; renal adjustment required.
• EACA: Less potent and used less commonly where TXA is available.

Choice between oral TXA and hormonal/IUD options for HMB depends on fertility plans, side‑effect preferences, and cultural or personal preferences.

FAQ — Canadian Patient Questions

• Is Cyklokapron covered by provincial plans? — Inpatient IV use is typically hospital-covered; outpatient oral coverage varies by province and may need special-authority from ODB, PharmaCare, or RAMQ.
• Can I take TXA with my birth control? — It is generally permitted, but combined estrogen-containing contraceptives increase thrombotic risk and require assessment of overall risk.
• Will TXA affect fertility? — No evidence suggests TXA affects fertility; it is used short-term for heavy menstrual bleeding management.
• Is TXA safe if I have kidney disease? — Dose adjustments are required for reduced renal function; consult the prescriber before use.
• Where can I get bilingual information? — Pharmacies such as Jean Coutu and larger chains provide English/French patient leaflets; Health Canada product monographs are available in both languages.

For complex comorbidities or conflicting medications, pharmacists should recommend specialist referral or prescriber discussion.

Guidelines For Proper Use — Pharmacist & Provincial Tips

Pharmacists need a short checklist before dispensing TXA.

• Verify indication and confirm no absolute contraindications.
• Check renal function where appropriate (CrCl particularly if <30 mL/min).
• Confirm allergy history, seizure history, and current anticoagulant or estrogen therapy.
• Ensure DIN and product monograph match the prescribed brand.

Use provincial portals (ODB, PharmaCare, RAMQ) for prior-authorizations and document counselling in pharmacy software.

For rural or remote patients, coordinate hospital supply, mail-order delivery from licensed Canadian pharmacies, and telehealth consults for specialist input.

Counsel on common side effects like headache and GI upset and advise patients to seek emergency care for signs of thrombosis (leg swelling, chest pain, sudden breathlessness) or seizures.

Delivery Across Canada (English)